Batiraxcept Combinations Under Further Investigation After Promising Efficacy Signals in Clear Cell RCCJune 26th 2022
Batiraxcept will continue to be investigated in combination with cabozantinib, plus in combination with cabozantinib and nivolumab and as a single agent, in patients with advanced or metastatic clear cell renal cell carcinoma in a phase 2 study.
PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPCJune 6th 2022
68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPCJune 5th 2022
The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.
177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After DocetaxelJune 5th 2022
177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities
Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial CancerJune 4th 2022
Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.
Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial CancerJune 4th 2022
Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.